After closing the deal, the company moved quickly to transfer its technology to Queensland-based Q-Gen Cell Therapeutics, with the handover currently on track.
Q-Gen has now taken over manufacturing StemSmart’s specialised stem cells from Royal Perth Hospital’s Cell and Tissue Centre as a key step towards scaling up production and paving the way for future commercial use.
NeuroScientific says more patients will receive stem cell therapy as new clinical applications get rolled out. The products will come from the East Metropolitan Health Service in Perth, which is already TGA-certified, or from Isopogen’s Queensland manufacturer once it gains final approval.
Beyond Crohn’s disease, NeuroScientific sees significant global potential for its StemSmart platform. The company is eyeing markets worth US$13.8 billion for Crohn’s by 2026, US$7.2 billion for kidney transplants by 2030, a massive US$33 billion lung disorder market by 2034 and US$5.31 billion for Graft-versus-host disease GvHD by 2032
With the first cohort of patients approved, manufacturing scale-up underway and Phase 2 planning locked in for 2026, NeuroScientific appears to be positioning StemSmart as a potential first-in-class therapy for patients with limited treatment options.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
